Teva Pharmaceutical ADR Aktie | Analysen | News | Kurse | Charts | Diskussionen | WKN 883035, ISIN US8816242098 | aktiencheck.de
Teva Pharmaceutical ADR Aktie | Analysen | News | Kurse | Charts | Diskussionen | WKN 883035, ISIN US8816242098 | aktiencheck.de
![Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol - 21.05.22 - News - ARIVA .DE Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol - 21.05.22 - News - ARIVA .DE](https://www.ariva.de/news/attachments/labormitarbeiter-bei-einer-untersuchung-symbolbild-biomarinpharmaceutical.jpg?optional=body&resize_x=960&resize_y=400&fid=9b9e27e4db2db888bc018e0a2fc42d3f)
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol - 21.05.22 - News - ARIVA .DE
![Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis - 20.05.22 - News - ARIVA.DE Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis - 20.05.22 - News - ARIVA.DE](https://www.ariva.de/news/attachments/eine-chemikerin-im-labor-symbolbild-celgene.jpg?optional=body&resize_x=960&resize_y=400&fid=078ec1ffb9b0b206ed128c4d11b77b40)